A meta-analysis of 1,458 adults showed kratom users had lower LDL cholesterol and triglycerides, higher HDL, and lower BMI—suggesting potential protective effects against metabolic syndrome. 1.
🧪 1. Meta‑Analysis of Cross‑Sectional Studies
A 2025 systematic review and meta‑analysis analyzed data from five cross‑sectional human studies (totaling 1,458 adults). Compared to non‑users, kratom users had:
- Lower LDL‑cholesterol by about 0.21 mmol/L (~8 mg/dL)
- Lower triglycerides by ~0.17 mmol/L (~15 mg/dL)
- Higher HDL‑cholesterol by ~0.07 mmol/L (~3 mg/dL)
- Lower BMI by ~1.5 kg/m²
Total cholesterol and blood glucose differences were not statistically significant.
📊 2. Individual Observational Studies
a) Thailand study – Metabolic Syndrome
- In rural Thailand, kratom users (n=285) had a Metabolic Syndrome (MetS) prevalence of ~11.9%, versus ~21.6% in non‑users—a 44% reduction in risk (adjusted OR ≈ 0.56)
- Users also exhibited smaller waist circumference, lower triglycerides, and higher HDL. There were no differences in fasting glucose or blood pressure .
b) Lipid Profile Study (HDL & Triglycerides)
- Another Thai study found kratom users had significantly elevated HDL levels (≥60 mg/dL, OR ≈1.82) and triglyceride levels <90 mg/dL (OR ≈1.75). No significant differences in LDL or total cholesterol in this cohort
c) Malaysian Study
- Among 200 participants (100 kratom users vs. 100 controls), kratom users had significantly lower total cholesterol and LDL levels, with no major differences in triglyceride or HDL levels. But heavier daily use correlated with higher cholesterol .
🔬 3. Preclinical Mechanisms from Lab Research
A 2025 lab (HepG2 cell) study showed that kratom leaf extracts (mitragynine, quercetin, rutin):
- Increased LDL receptor (LDLR) expression
- Decreased PCSK9 expression
- Enhanced LDL uptake in liver cells
This suggests a biological basis for cholesterol‑lowering effects.
Further, other research indicates kratom compounds can inhibit digestive enzymes like lipase, alpha‑glucosidase, and ACC1, reducing fat digestion and storage—potentially explaining the observed reductions in triglycerides and BMI
✅ Summary Table
| Outcome | Meta‑Analysis / Observational Evidence | Mechanistic Insight |
|---|---|---|
| LDL‑cholesterol | ↓ ≈ 8 mg/dL overall; lower in some studies | ↑ LDLR / ↓ PCSK9 expression |
| Triglycerides | ↓ ≈ 15 mg/dL overall; lower odds in users | Lipase & ACC1 inhibition reduces fat uptake |
| HDL‑cholesterol | ↑ ≈ 3 mg/dL overall; elevated levels in studies | Possible HDL-related pathways unknown |
| BMI / Waist size | BMI ↓ ~1.5 kg/m²; smaller waist in users | Reduced lipogenesis via ACC1/quercetin |
⚠️ Caveats & Context
- All human data are observational cross‑sectional, meaning no causal inferences can be made.
- Potential confounding factors (diet, exercise, tobacco use, traditional lifestyles) may influence results.
- Higher frequency or heavier kratom use could be associated with increased cholesterol, as seen in some studies.
- The sample sizes remain modest (hundreds), and consistency across different populations isn’t guaranteed.
- Clinical trials are needed for confirmation.
🧠 Final Thoughts
The available human and lab-based evidence suggests that kratom use correlates with modest improvements in lipid profiles and body composition, including lower LDL, lower triglycerides, higher HDL, and lower BMI/waist circumference. Lab studies further support plausible mechanisms involving LDL receptor regulation and inhibition of fat digestion pathways.
Still, these findings are preliminary and correlational. More rigorous research—including longitudinal and randomized trials—is essential to verify safety, dosage, and effectiveness.
——————-